Abstract: The invention provides a ready to use biodegradable and biocompatible device and a method for manufacturing thereof. The device of present invention is a novel porous scaffold which can be used as carrier of plurality of therapeutics to quickly stop bleeding and other biomaterial and biomedical application. The scaffold can be directly applied to the spot of the wound and will stop bleeding within no time. The scaffold of the present invention comprises of combined application of air dry and freeze dry method. The scaffold also comprises of excellent ventilations properties and easy removal of the scaffold without causing any extra hemorrhage to the wound.

Abstract: Methods and devices are provided for activating brown adipose tissue with targeted substance delivery. Generally, the methods and devices can activate BAT to increase thermogenesis, e.g., increase heat production in the patient, which over time can lead to weight loss and/or improved metabolic function. In one embodiment, a chemical configured to stimulate nerves that activate the BAT and/or to stimulate brown adipocytes directly can be delivered to a patient, thereby increasing thermogenesis in the BAT and inducing weight loss and/or improved metabolic function through energy expenditure. The chemical can be delivered to the patient locally and/or systemically to stimulate the nerves and/or the brown adipocytes.

Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.

Abstract: The invention provides pharmaceutical formulations of inhibitors for poly (ADP-ribose) polymerase (PARP) enzyme. The formulations can be used in the treatment and prevention of cancer as well as the treatment of neurotrauma and neurodegenerative diseases. The PARP inhibitor is delivered in the form of nanoparticles that provide efficient delivery of the inhibitor into cancer cells or other cells and release of the inhibitor within the cells. In treating cancer, the result is killing of tumor cells, whereas in treatment of neurotrauma and neurodegenerative disease, the result is preservation of cell function.

Abstract: The deodorant composition of the present invention includes an amorphous aluminum silicate, a hydrazide compound, and a crystalline zinc oxide in which at least two peaks among three peaks detected within a diffraction angle (2?) range from 30 to 38 degrees when the crystalline zinc oxide is subjected to X-ray powder diffraction measurement have a half width of 0.4 to 1.2 degrees in an X-ray diffraction chart, wherein a content of the crystalline zinc oxide is in a range from 100 to 500 parts by mass based on 100 parts by mass of the hydrazide compound, and wherein a content of the amorphous aluminum silicate is in a range from 100 to 750 parts by mass based on 100 parts by mass of the hydrazide compound.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.

Abstract: The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time.

Abstract: Clay composite sheets, mats, films or membranes without polymers. Methods of preparing clay composite sheets, mats, films or membranes without using polymers in the method. Methods of using clay composite sheets, mats, films or membranes prepared without using polymers. Antimicrobial dressing having organo-modified clay product. Transdermal delivery of drugs using organo-modified clay product and methods.

Abstract: The present invention is directed to a new pharmaceutical dosage form comprising mesoporous particles loaded with a poorly soluble active pharmaceutical ingredient, the particles being at least partially, preferably homogeneously, covered with a polymer solid dispersion.

Abstract: The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG.

Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.

Abstract: A cosmetic or dermatological system includes a receiver of data related to current and/or future surrounding conditions transmitted by a data transmitter external to the system, a packaging and dispenser device containing one or more compositions from which a preparation is delivered, an adjustment system that is coupled to or suitable for coupling to the packaging and dispenser device, and that enables at least one characteristic of the dispensed preparation to be varied, and a processor for automatically controlling the adjustment system as a function of the received data or for informing the user, as a function of the received data, about an action to be exerted on the adjustment system.

Abstract: A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of the plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron.

Abstract: A composition is described that may be used in personal care products. The composition can serve as a preservative. In addition or alternatively, the composition may serve as a fragrance and/or as a coloring agent. The composition can contain an active compound, an organic acid, a solvent, and optionally a dispersant. In one embodiment, the active compound and the organic acid comprise all natural ingredients.

Abstract: The present application provides an oil-in-water type emulsified cosmetic which has the effect of beautifying the appearance of skin and also excels in emulsion stability. The oil-in-water type emulsified cosmetic according to the present invention is characterized by comprising (A) 1 to 20 mass % of a hydrophobized titanium oxide having an average particle size of at least 0.1 ?m; (B) a sugar ester having a carboxyl group within the structure; (C) a liquid higher fatty acid; (D) a higher alcohol; (E) a non-ionic surfactant; (F) water; and (G) an oil component.

Abstract: The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight of 50-1,000 mg and containing at least 0.1 mg of an estetrol component selected from estetrol, estetrol esters and combinations thereof. This solid dosage unit consists of: 4-95 wt. % of granules consisting of: 3-80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; 20-97 wt. % C4-C12 sugar alcohol; 0-45 wt. % of one or more other pharmaceutically acceptable ingredients; and 5-96 wt. % of one or more pharmaceutically acceptable excipients. The solid dosage units of the present invention are particularly suited for sublingual, buccal or sublabial administration of the estetrol component.

Abstract: A cationic star polymer is disclosed of the general formula (1): wherein w? is a positive number greater than or equal to 3, I? is a dendritic polyester core covalently linked to w? independent peripheral linear cationic polymer chains P?. Each of the chains P? comprises a cationic repeat unit comprising i) a backbone functional group selected from the group consisting of aliphatic carbonates, aliphatic esters, aliphatic carbamates, aliphatic ureas, aliphatic thiocarbamates, aliphatic dithiocarbonates, and combinations thereof, and ii) a side chain comprising a quaternary amine group. The quaternary amine group comprises a divalent methylene group directly covalently linked to i) a positive charged nitrogen and ii) an aromatic ring.

Abstract: An improved manufacturing process produces microcrystalline hydroxyapatrte with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products.

Abstract: The antimicrobial foaming composition of the present invention comprises a cationic active ingredient, a cationic compatible surfactant, a foam booster, a foam structure enhancing agent, dermal adjuvants, and a carrier. The present antimicrobial compositions are free of the antimicrobial agents triclosan (i.e., 2,4,4?-trichloro-2?hydroxy-diphenylether) and lower alcohols. They are also free of anionic surfactants. The foaming compositions have rapid cidal activity, provide stable, copious foam, and exhibit enhanced tissue (e.g. skin) compatibility.

Abstract: A composition and a method of applying the composition to a site on or within a body of a mammal. The composition includes a hydrogel matrix that includes at least one polymer cross linked, via ionic or covalent bonding, with both hyaluronic acid and alginic acid. The at least one polymer is chitosan, poly L-Lysine, or a combination thereof.